---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008469"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:14:41.804688+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enanta reports Q2 net loss of $33.6M; revenue down to $18.7M on lower HCV royalties

## Summary
- Net loss of $33.6M ($1.63/share) vs. loss of $22.0M ($1.09/share) last year.
- Total revenue of $18.7M, down 7% YoY, all royalty from AbbVie's HCV regimen MAVYRET.
- Cash and securities $322.5M; expects to fund operations for at least two years.
- Expects topline data from RSVP Phase 2b study of EDP-938 in adults with RSV this quarter.
- FDA Fast Track for EDP-235 (COVID-19); preliminary Phase 1 data expected this quarter.

## SEC filing metadata
- accession: 0000950170-22-008469
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017022008469/0000950170-22-008469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017022008469/enta-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008469
- JSON: https://secwatch.observer/filing/0000950170-22-008469.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.